CL2018000282A1 - Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol - Google Patents

Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol

Info

Publication number
CL2018000282A1
CL2018000282A1 CL2018000282A CL2018000282A CL2018000282A1 CL 2018000282 A1 CL2018000282 A1 CL 2018000282A1 CL 2018000282 A CL2018000282 A CL 2018000282A CL 2018000282 A CL2018000282 A CL 2018000282A CL 2018000282 A1 CL2018000282 A1 CL 2018000282A1
Authority
CL
Chile
Prior art keywords
gamma
treatment
hydroxybutyric acid
alcohol abuse
selected amide
Prior art date
Application number
CL2018000282A
Other languages
English (en)
Spanish (es)
Inventor
Roberto Cacciaglia
Antonella Loche
Original Assignee
Laboratorio Farm C T S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Farm C T S R L filed Critical Laboratorio Farm C T S R L
Publication of CL2018000282A1 publication Critical patent/CL2018000282A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2018000282A 2015-08-04 2018-01-31 Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol CL2018000282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2015A002860A ITUB20152860A1 (it) 2015-08-04 2015-08-04 Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool

Publications (1)

Publication Number Publication Date
CL2018000282A1 true CL2018000282A1 (es) 2018-07-13

Family

ID=54542363

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000282A CL2018000282A1 (es) 2015-08-04 2018-01-31 Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol

Country Status (24)

Country Link
US (1) US10336687B2 (OSRAM)
EP (1) EP3331853B1 (OSRAM)
JP (1) JP6832336B2 (OSRAM)
KR (1) KR102817897B1 (OSRAM)
CN (1) CN108026029B (OSRAM)
AU (1) AU2016302869B2 (OSRAM)
CA (1) CA2994599C (OSRAM)
CL (1) CL2018000282A1 (OSRAM)
CO (1) CO2018002428A2 (OSRAM)
DK (1) DK3331853T3 (OSRAM)
EA (1) EA033769B9 (OSRAM)
ES (1) ES2776628T3 (OSRAM)
GE (1) GEP20207107B (OSRAM)
IL (1) IL257314B (OSRAM)
IT (1) ITUB20152860A1 (OSRAM)
MX (1) MX2018001239A (OSRAM)
MY (1) MY185942A (OSRAM)
PH (1) PH12018550008A1 (OSRAM)
PL (1) PL3331853T3 (OSRAM)
PT (1) PT3331853T (OSRAM)
SM (1) SMT202000337T1 (OSRAM)
UA (1) UA121994C2 (OSRAM)
WO (1) WO2017021438A1 (OSRAM)
ZA (1) ZA201801402B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US12201612B2 (en) 2017-07-31 2025-01-21 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
CN113185403A (zh) * 2021-07-02 2021-07-30 山东国邦药业有限公司 一种甲醚制备环丙胺中间体环丙甲酸甲酯的方法
WO2023126076A1 (en) * 2022-01-03 2023-07-06 Laboratorio Farmaceutico C.T. S.R.L. Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283782B1 (it) * 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo

Also Published As

Publication number Publication date
CA2994599C (en) 2023-08-29
GEP20207107B (en) 2020-05-11
KR20180066033A (ko) 2018-06-18
AU2016302869B2 (en) 2020-10-22
CN108026029B (zh) 2020-12-04
WO2017021438A1 (en) 2017-02-09
CN108026029A (zh) 2018-05-11
BR112018002245A2 (pt) 2018-09-18
IL257314B (en) 2020-04-30
EA033769B9 (ru) 2020-04-10
PL3331853T3 (pl) 2020-06-15
US20180230086A1 (en) 2018-08-16
IL257314A (en) 2018-03-29
DK3331853T3 (da) 2020-03-16
EA033769B1 (ru) 2019-11-22
GEAP202014717A (en) 2020-01-27
SMT202000337T1 (it) 2020-07-08
ZA201801402B (en) 2019-01-30
PH12018550008A1 (en) 2018-07-09
JP2018523644A (ja) 2018-08-23
PT3331853T (pt) 2020-02-25
UA121994C2 (uk) 2020-08-25
EP3331853B1 (en) 2019-12-11
CA2994599A1 (en) 2017-02-09
KR102817897B1 (ko) 2025-06-05
MY185942A (en) 2021-06-14
MX2018001239A (es) 2018-07-06
CO2018002428A2 (es) 2018-07-10
JP6832336B2 (ja) 2021-02-24
EA201890419A1 (ru) 2018-07-31
AU2016302869A1 (en) 2018-03-15
US10336687B2 (en) 2019-07-02
ITUB20152860A1 (it) 2017-02-04
EP3331853A1 (en) 2018-06-13
ES2776628T3 (es) 2020-07-31

Similar Documents

Publication Publication Date Title
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
GT201600070A (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017001046A1 (es) Inhibidoes del bromodominio
CR20160275A (es) Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b
DOP2016000253A (es) Nuevos compuestos
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112017008481A2 (pt) composto antimicótico
CL2018000282A1 (es) Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX390011B (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2019002259A (es) Inhibicion de la actividad de la olig2.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
CL2017002229A1 (es) Inhibidores de bace1.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза